Open Nav

BlackThorn Therapeutics

  • Greg Vontz, BlackThorn Therapeutics

Provide investors with a progress update on the company’s pipeline and clinical programs; create

  • Date:Wednesday, October 17
  • Time:2:45 PM - 3:00 PM
  • Room:Elizabethan C
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:BlackThorn Therapeutics is a clinical-stage biopharmaceutical company that uses a novel and robust approach to link behavioral deficits with brain physiology to discover and develop targeted treatments for neurobehavioral disorders. We envision a future where patients with neurobehavioral disorders are quickly recognized, accurately diagnosed and effectively treated.
  • Company
  • Company HQ City:San Francisco
  • Company HQ Country:United States
  • Company HQ State:California                  
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development :NOPR antagonist in clinical development for anhedonic dimensions of MDD
  • Development Phase of Primary Product:Phase II
  • Total Amount Raised to Date, In All Rounds:$54M Series A, currently raising Series B
Greg Vontz
BlackThorn Therapeutics